Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Correlia Bio develops the PIXI platform, a benchtop automated immunoassay system that uses proprietary microfluidic gel technology to quantify proteins from samples as small as 1 uL. Aimed at pharmaceutical and proteomics researchers, it offers a faster alternative to traditional ELISA for protein measurement in laboratory workflows.
6 investors
Crescendo Biologics develops T cell enhancing therapeutics for immuno-oncology, based on its Humabody platform, with clinical candidates including the bispecific CB307 and immune cell engager CB699. Its pipeline targets cancers such as metastatic castration-resistant prostate cancer, and it partners with companies like Zai Lab on additional Humabody-derived treatments.
6 investors
Culture Biosciences provides software and bioreactor hardware solutions for bioprocess development, enabling researchers to design, monitor, and analyze experiments remotely with cloud-native analytics and AI/ML insights.
6 investors
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.
6 investors
Deep Genomics develops AI-based biological foundation models to identify drug targets and design molecules, aiming to speed up drug discovery. Its platform combines lab-in-the-loop workflows, training datasets, and screening technologies to find candidates for developing new medicines.
6 investors
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research. The company applies discovery approaches based on academic work in genetics and cancer biology.
6 investors
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
6 investors
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need. It is led by a team of scientists and industry veterans across chemistry, clinical development, and medical affairs.
6 investors
DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis. It serves biomedical organizations including pharmaceutical companies, clinical diagnostics providers, academic medical centers, and biobanks, with built-in GxP and regulatory compliance.
6 investors
Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases. The company works with pharmaceutical partners including Novartis, Sarepta, Roche, Spark, and Astellas to advance therapies for patients with genetic disorders.
6 investors
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.
6 investors
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
6 investors
Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions. The company serves a global customer base across 40+ countries in the life sciences and genomics industry.
6 investors
Embark Veterinary develops dog DNA tests and science-backed supplements for dog health and genetics. The company serves dog owners seeking genetic insights and nutritional products for their pets.
6 investors
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.
6 investors
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment. Its technology aims to selectively and durably modify cells of the hematopoietic system for patients.
6 investors
Entocycle uses industrial automation and machine learning to convert organic waste into animal and plant feed by breeding black soldier fly larvae at scale. The company addresses protein demand and food waste in global agriculture and aquaculture.
6 investors
Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
6 investors
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.
6 investors
FairCraft develops lab-grown leather produced from cells and proteins through a material discovery platform, offering an animal-free alternative with low environmental impact. The company creates cell-based materials that brands can fine-tune for touch, feel, and transformability properties.
6 investors
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans. The biotech company focuses on discovering novel therapeutics for human diseases based on evolutionary and genomic insights.
6 investors
Freedom Biosciences develops neuropsychiatric therapeutics, focusing on novel treatments for conditions including depression, PTSD, and alcoholism. The company advances drug candidates through clinical development and regulatory pathways, serving patients with mental health and neurological disorders.
6 investors
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells. A spin-out of the Centre for Probe Development and Commercialization, it focuses on radiopharmaceuticals for cancer treatment.
6 investors
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.
6 investors